Drug profile · INN
rufinamide
INOVELON
rufinamide (INOVELON) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Drug details — rufinamide
- US status
- approved
- Class
- Nervous system (N03)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
rufinamide (INOVELON) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is rufinamide?
rufinamide (INOVELON) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rufinamide?
INOVELON is a marketed brand name for rufinamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rufinamide?
rufinamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.